Protective effects of soluble collagen during ultraviolet-a crosslinking on enzyme-mediated corneal ectatic models

Xiaokun Wang, Yong Huang, Sabah Jastaneiah, Shoumyo Majumdar, Jin U. Kang, Samuel Chi-Hung Yiu, Walter Stark, Jennifer Hartt Elisseeff

Research output: Contribution to journalArticle

Abstract

Collagen crosslinking is a relatively new treatment for structural disorders of corneal ectasia, such as keratoconus. However, there is a lack of animal models of keratoconus, which has been an obstacle for carefully analyzing the mechanisms of crosslinking and evaluating new therapies. In this study, we treated rabbit eyes with collagenase and chondroitinase enzymes to generate ex vivo corneal ectatic models that simulate the structural disorder of keratoconus. The models were then used to evaluate the protective effect of soluble collagen in the UVA crosslinking system. After enzyme treatment, the eyes were exposed to riboflavin/UVA crosslinking with and without soluble type I collagen. Corneal morphology, collagen ultrastructure, and thermal stability were evaluated before and after crosslinking. Enzyme treatments resulted in corneal curvature changes, collagen ultrastructural damage, decreased swelling resistance and thermal stability, which are similar to what is observed in keratoconus eyes. UVA crosslinking restored swelling resistance and thermal stability, but ultrastructural damage were found in the crosslinked ectatic corneas. Adding soluble collagen during crosslinking provided ultrastructural protection and further enhanced the swelling resistance. Therefore, UVA crosslinking on the ectatic model mimicked typical clinical treatment for keratoconus, suggesting that this model replicates aspects of human keratoconus and could be used for investigating experimental therapies and treatments prior to translation.

Original languageEnglish (US)
Article numbere0136999
JournalPLoS One
Volume10
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Keratoconus
crosslinking
Crosslinking
protective effect
collagen
Collagen
Enzymes
enzymes
Hot Temperature
thermal stability
Swelling
Thermodynamic stability
eyes
enzymatic treatment
Therapeutics
Chondroitinases and Chondroitin Lyases
Pathologic Dilatations
Investigational Therapies
Riboflavin
Structural Models

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Protective effects of soluble collagen during ultraviolet-a crosslinking on enzyme-mediated corneal ectatic models. / Wang, Xiaokun; Huang, Yong; Jastaneiah, Sabah; Majumdar, Shoumyo; Kang, Jin U.; Yiu, Samuel Chi-Hung; Stark, Walter; Elisseeff, Jennifer Hartt.

In: PLoS One, Vol. 10, No. 9, e0136999, 01.09.2015.

Research output: Contribution to journalArticle

@article{858c2bcc8add487f8b531ff5d1e812e2,
title = "Protective effects of soluble collagen during ultraviolet-a crosslinking on enzyme-mediated corneal ectatic models",
abstract = "Collagen crosslinking is a relatively new treatment for structural disorders of corneal ectasia, such as keratoconus. However, there is a lack of animal models of keratoconus, which has been an obstacle for carefully analyzing the mechanisms of crosslinking and evaluating new therapies. In this study, we treated rabbit eyes with collagenase and chondroitinase enzymes to generate ex vivo corneal ectatic models that simulate the structural disorder of keratoconus. The models were then used to evaluate the protective effect of soluble collagen in the UVA crosslinking system. After enzyme treatment, the eyes were exposed to riboflavin/UVA crosslinking with and without soluble type I collagen. Corneal morphology, collagen ultrastructure, and thermal stability were evaluated before and after crosslinking. Enzyme treatments resulted in corneal curvature changes, collagen ultrastructural damage, decreased swelling resistance and thermal stability, which are similar to what is observed in keratoconus eyes. UVA crosslinking restored swelling resistance and thermal stability, but ultrastructural damage were found in the crosslinked ectatic corneas. Adding soluble collagen during crosslinking provided ultrastructural protection and further enhanced the swelling resistance. Therefore, UVA crosslinking on the ectatic model mimicked typical clinical treatment for keratoconus, suggesting that this model replicates aspects of human keratoconus and could be used for investigating experimental therapies and treatments prior to translation.",
author = "Xiaokun Wang and Yong Huang and Sabah Jastaneiah and Shoumyo Majumdar and Kang, {Jin U.} and Yiu, {Samuel Chi-Hung} and Walter Stark and Elisseeff, {Jennifer Hartt}",
year = "2015",
month = "9",
day = "1",
doi = "10.1371/journal.pone.0136999",
language = "English (US)",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Protective effects of soluble collagen during ultraviolet-a crosslinking on enzyme-mediated corneal ectatic models

AU - Wang, Xiaokun

AU - Huang, Yong

AU - Jastaneiah, Sabah

AU - Majumdar, Shoumyo

AU - Kang, Jin U.

AU - Yiu, Samuel Chi-Hung

AU - Stark, Walter

AU - Elisseeff, Jennifer Hartt

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Collagen crosslinking is a relatively new treatment for structural disorders of corneal ectasia, such as keratoconus. However, there is a lack of animal models of keratoconus, which has been an obstacle for carefully analyzing the mechanisms of crosslinking and evaluating new therapies. In this study, we treated rabbit eyes with collagenase and chondroitinase enzymes to generate ex vivo corneal ectatic models that simulate the structural disorder of keratoconus. The models were then used to evaluate the protective effect of soluble collagen in the UVA crosslinking system. After enzyme treatment, the eyes were exposed to riboflavin/UVA crosslinking with and without soluble type I collagen. Corneal morphology, collagen ultrastructure, and thermal stability were evaluated before and after crosslinking. Enzyme treatments resulted in corneal curvature changes, collagen ultrastructural damage, decreased swelling resistance and thermal stability, which are similar to what is observed in keratoconus eyes. UVA crosslinking restored swelling resistance and thermal stability, but ultrastructural damage were found in the crosslinked ectatic corneas. Adding soluble collagen during crosslinking provided ultrastructural protection and further enhanced the swelling resistance. Therefore, UVA crosslinking on the ectatic model mimicked typical clinical treatment for keratoconus, suggesting that this model replicates aspects of human keratoconus and could be used for investigating experimental therapies and treatments prior to translation.

AB - Collagen crosslinking is a relatively new treatment for structural disorders of corneal ectasia, such as keratoconus. However, there is a lack of animal models of keratoconus, which has been an obstacle for carefully analyzing the mechanisms of crosslinking and evaluating new therapies. In this study, we treated rabbit eyes with collagenase and chondroitinase enzymes to generate ex vivo corneal ectatic models that simulate the structural disorder of keratoconus. The models were then used to evaluate the protective effect of soluble collagen in the UVA crosslinking system. After enzyme treatment, the eyes were exposed to riboflavin/UVA crosslinking with and without soluble type I collagen. Corneal morphology, collagen ultrastructure, and thermal stability were evaluated before and after crosslinking. Enzyme treatments resulted in corneal curvature changes, collagen ultrastructural damage, decreased swelling resistance and thermal stability, which are similar to what is observed in keratoconus eyes. UVA crosslinking restored swelling resistance and thermal stability, but ultrastructural damage were found in the crosslinked ectatic corneas. Adding soluble collagen during crosslinking provided ultrastructural protection and further enhanced the swelling resistance. Therefore, UVA crosslinking on the ectatic model mimicked typical clinical treatment for keratoconus, suggesting that this model replicates aspects of human keratoconus and could be used for investigating experimental therapies and treatments prior to translation.

UR - http://www.scopus.com/inward/record.url?scp=84943302924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943302924&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0136999

DO - 10.1371/journal.pone.0136999

M3 - Article

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e0136999

ER -